These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 14970872)

  • 1. Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice.
    Ching LM; Zwain S; Baguley BC
    Br J Cancer; 2004 Feb; 90(4):906-10. PubMed ID: 14970872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of endothelial cell apoptosis by the antivascular agent 5,6-Dimethylxanthenone-4-acetic acid.
    Ching LM; Cao Z; Kieda C; Zwain S; Jameson MB; Baguley BC
    Br J Cancer; 2002 Jun; 86(12):1937-42. PubMed ID: 12085190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of tumor vascular shutdown induced by 5,6-dimethylxanthenone-4-acetic acid (DMXAA): Increased tumor vascular permeability.
    Zhao L; Ching LM; Kestell P; Kelland LR; Baguley BC
    Int J Cancer; 2005 Aug; 116(2):322-6. PubMed ID: 15800918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Consequences of increased vascular permeability induced by treatment of mice with 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and thalidomide.
    Chung F; Liu J; Ching LM; Baguley BC
    Cancer Chemother Pharmacol; 2008 Mar; 61(3):497-502. PubMed ID: 17473922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid.
    Cao Z; Joseph WR; Browne WL; Mountjoy KG; Palmer BD; Baguley BC; Ching LM
    Br J Cancer; 1999 May; 80(5-6):716-23. PubMed ID: 10360649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice.
    Ching LM; Goldsmith D; Joseph WR; Körner H; Sedgwick JD; Baguley BC
    Cancer Res; 1999 Jul; 59(14):3304-7. PubMed ID: 10416582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice.
    Zhao L; Ching LM; Kestell P; Baguley BC
    Br J Cancer; 2002 Aug; 87(4):465-70. PubMed ID: 12177785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of serum tumour necrosis factor-alpha by thalidomide does not lead to reversal of tumour vascular collapse and anti-tumour activity of 5,6-dimethylxanthenone-4-acetic acid.
    Browne WL; Wilson WR; Baguley BC; Ching LM
    Anticancer Res; 1998; 18(6A):4409-13. PubMed ID: 9891501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of tumour necrosis factor-alpha by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid.
    Philpott M; Baguley BC; Ching LM
    Cancer Chemother Pharmacol; 1995; 36(2):143-8. PubMed ID: 7767951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the serotonin receptor antagonist cyproheptadine on the activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
    Zhao L; Kestell P; Philpott M; Ching LM; Zhuang L; Baguley BC
    Cancer Chemother Pharmacol; 2001 Jun; 47(6):491-7. PubMed ID: 11459201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid: a novel approach to cancer therapy.
    Joseph WR; Cao Z; Mountjoy KG; Marshall ES; Baguley BC; Ching LM
    Cancer Res; 1999 Feb; 59(3):633-8. PubMed ID: 9973211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Visualizing the acute effects of vascular-targeted therapy in vivo using intravital microscopy and magnetic resonance imaging: correlation with endothelial apoptosis, cytokine induction, and treatment outcome.
    Seshadri M; Spernyak JA; Maiery PG; Cheney RT; Mazurchuk R; Bellnier DA
    Neoplasia; 2007 Feb; 9(2):128-35. PubMed ID: 17356709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice.
    Zhao L; Kestell P; Ching LM; Baguley BC
    Cancer Chemother Pharmacol; 2002 Jan; 49(1):20-6. PubMed ID: 11855749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NF-kappa B activation in vivo in both host and tumour cells by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
    Woon ST; Zwain S; Schooltink MA; Newth AL; Baguley BC; Ching LM
    Eur J Cancer; 2003 May; 39(8):1176-83. PubMed ID: 12736120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NF-kappaB-independent induction of endothelial cell apoptosis by the vascular disrupting agent DMXAA.
    Woon ST; Hung SS; Wu DC; Schooltink MA; Sutherland R; Baguley BC; Chen Q; Chamley LW; Ching LM
    Anticancer Res; 2007; 27(1A):327-34. PubMed ID: 17352250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor vascular response to photodynamic therapy and the antivascular agent 5,6-dimethylxanthenone-4-acetic acid: implications for combination therapy.
    Seshadri M; Spernyak JA; Mazurchuk R; Camacho SH; Oseroff AR; Cheney RT; Bellnier DA
    Clin Cancer Res; 2005 Jun; 11(11):4241-50. PubMed ID: 15930363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon-inducible protein 10 induction and inhibition of angiogenesis in vivo by the antitumor agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
    Cao Z; Baguley BC; Ching LM
    Cancer Res; 2001 Feb; 61(4):1517-21. PubMed ID: 11245459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid: concomitant reduction of serum tumour necrosis factor-alpha and enhancement of anti-tumour activity.
    Ching LM; Browne WL; Tchernegovski R; Gregory T; Baguley BC; Palmer BD
    Br J Cancer; 1998 Aug; 78(3):336-43. PubMed ID: 9703279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of tumour necrosis factor and interferon-gamma in cultured murine splenocytes by the antivascular agent DMXAA and its metabolites.
    Wang LC; Reddy CB; Baguley BC; Kestell P; Sutherland R; Ching LM
    Biochem Pharmacol; 2004 Mar; 67(5):937-45. PubMed ID: 15104247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p38 mitogen-activated protein kinase is required for the antitumor activity of the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid.
    Wu Q; Quan H; Xu Y; Li Y; Hu Y; Lou L
    J Pharmacol Exp Ther; 2012 Jun; 341(3):709-17. PubMed ID: 22414857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.